Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

A Phase Ib/11 Study of Propranolol with fixed-dose Pembrolizumab in Patients with Unresectable Stage III and Stage IV Melanoma

This research is being done to find out the safety of propranolol and, identify the maximum tolerated dose of propranolol that can be administered in combination with pembrolizumab in patients with unresectable stage III and stage IV melanoma. This study will evaluate this novel combination of pembrolizumab and propranolol to see what effect it may have on how your cancer responds to the treatment combination.

Phase II *propranolol twice a day. *pembrolizumab by an infusion every 3 weeks. *May receive treatment with pembrolizumab and propranolol for up to 24 months from the time they began treatment with the combination. Procedures to be done:.  A medical history  A physical exam  ECOG Performance Status  Perceived Stress Scale questionnaire  An assessment of tumor by scan. Scans may include: o Computed tomography (CT), with or without contrast. o Magnetic resonance imaging (MRI) or head CT with IV contrast  Blood tests: o Approximately 2 tablespoons for routine testing, such as a complete blood count and a comprehensive metabolic panel  Pregnancy test  Urinalysis  Electrocardiogram  A sample of tumor from a previous biopsy or sample taken Phase 1 portion of the study, these evaluations/tests will also occur on Day 8 of Cycle 1  Review concomitant medications.  Physical Exams  ECOG Performance Status  Perceived Stress Scale questionnaire  Blood tests: o Every 3 weeks o At 3 weeks and 6 months or discontinuation of treatment (whichever comes sooner) and at disease progression o Every 3 weeks: Approximately 1 tablespoon for tests that monitor your blood sugar levels and thyroid function o Every week for the first 6 weeks then every cycle for another 6 weeks  Assessment of cancer by CT or MRI. These assessments will be performed every 12 weeks(± 14 days). The first assessment will be after completing Cycle 4. If their cancer is found to be improving, repeat the CT and MRI scans in about 12 weeks.  EKG: Once treatment begins, this will be done every cycle prior to receiving pembrolizumab for the first 5 cycles.  Adverse events  Tumor Biopsy: A tumor biopsy (only in phase II) will be obtained at the 12 weeks after initiation of treatment.Tumor biopsy will be optional for phase II patients.. Safety Follow-Up: After all study treatment has stopped, end of treatment visit, which will be approximately 30 days after their last dose of study drug or before starting a new treatment  Medical History:  Concomitant medications  complete physical examination  ECOG Performance Status  Perceived Stress Scale assessment  Adverse events  Survival status  Blood tests: o Follow- Up Phase 3 Month and 6 Month Follow- up After Treatment blood collected. The following assessments will be performed at 3 months and 6 months after the safety follow-up visit. Review concomitant medications  Physical examination  ECOG Performance Status  Adverse events  Survival Status  Blood tests:  CT of chest, abdomen and pelvis, or other areas as needed Long Term Survival Follow- Up: After your 3 month and 6 month follow up visits or if they progress, will be contacted every 6 months (±30 days)


Joseph Drabick 717-531-5471
Medicine: Hematology and Medical Oncology (HERSHEY)

18 year(s) or older
This study is NOT accepting healthy volunteers
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Age >=18 years.
Participants must be newly diagnosed, treatment-naive with histologically confirmed stage IIIC unresectable melanoma or stage IV melanoma.
Have measurable disease per RECIST v1.1
Have an ECOG performance status 0-1

Exclusion Criteria:
Participants who have received previous immunotherapy for any cancer (excluding melanoma) including PD-1/PD-L1 inhibitors but not interferons and CTLA-4 inhibitors.
Participants with chronic autoimmune diseases
Other invasive cancers diagnosed < 3 years back that required systemic treatment. If diagnosed with other invasive cancer ≥ 3 years, should have complete recovery from all systemic toxicity except neuropathy and alopecia
I'm interested
Share via email
See this study on
Show 1 location

Study Locations

Hide all locations
Location Contacts
Hershey, PA ,